Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger von Moos

Showing results (51-60 of 129) with videos related to

Pageof 13
Sort By:
Oncology|December 19, 2007
Pegylated liposomal doxorubicin (caelyx) in metastatic breast cancer: a community-based observation studyMarc Salzberg, Beat Thurlimann, Ursula Hasler, et al.
Current Medical Research and Opinion|December 15, 2018
Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in the United StatesDavid Henry, Roger von Moos, Jean-Jacques Body, et al.
Case Reports in Oncology|June 29, 2012
Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art TechniquesNicola L Schoenewolf, Reinhard Dummer, Daniela Mihic-Probst, et al.
Onkologie|June 5, 2010
Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03)Roger von Moos, Arnaud Roth, Thomas Ruhstaller, et al.
Investigational New Drugs|August 28, 2021
A phase I trial of lurbinectedin in combination with cisplatin in patients with advanced solid tumorsYannis Metaxas, Carmen Kahatt, Vicente Alfaro, et al.
Bone Reports|August 14, 2024
Are bone targeted agents still useful in times of immunotherapy? The SAKK 80/19 BTA pilot studyMichael Mark, Alfonso Rojas Mora, Thomas Winder, et al.
BMC Health Services Research|July 5, 2018
Physicians' preferences for bone metastases treatments in France, Germany and the United KingdomYi Qian, Jorge Arellano, Francesca Gatta, et al.
Oncology|November 2, 2011
Trastuzumab treatment beyond progression in advanced breast cancer: patterns of care in six Swiss breast cancer centersJens Huober, Michael Baumann, Christoph Rochlitz, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 30, 2016
Burden of symptoms associated with development of metastatic bone disease in patients with breast cancerCharles Cleeland, Roger von Moos, Mark S Walker, et al.
Clinical Genitourinary Cancer|January 29, 2019
Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot StudyMichael Mark, Dirk Klingbiel, Ulrich Mey, et al.
Pageof 13

Showing results (51-60 of 129) with videos related to

Sort By:
Pageof 13
Oncology|December 19, 2007
Pegylated liposomal doxorubicin (caelyx) in metastatic breast cancer: a community-based observation studyMarc Salzberg, Beat Thurlimann, Ursula Hasler, et al.
Current Medical Research and Opinion|December 15, 2018
Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in the United StatesDavid Henry, Roger von Moos, Jean-Jacques Body, et al.
Case Reports in Oncology|June 29, 2012
Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art TechniquesNicola L Schoenewolf, Reinhard Dummer, Daniela Mihic-Probst, et al.
Onkologie|June 5, 2010
Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03)Roger von Moos, Arnaud Roth, Thomas Ruhstaller, et al.
Investigational New Drugs|August 28, 2021
A phase I trial of lurbinectedin in combination with cisplatin in patients with advanced solid tumorsYannis Metaxas, Carmen Kahatt, Vicente Alfaro, et al.
Bone Reports|August 14, 2024
Are bone targeted agents still useful in times of immunotherapy? The SAKK 80/19 BTA pilot studyMichael Mark, Alfonso Rojas Mora, Thomas Winder, et al.
BMC Health Services Research|July 5, 2018
Physicians' preferences for bone metastases treatments in France, Germany and the United KingdomYi Qian, Jorge Arellano, Francesca Gatta, et al.
Oncology|November 2, 2011
Trastuzumab treatment beyond progression in advanced breast cancer: patterns of care in six Swiss breast cancer centersJens Huober, Michael Baumann, Christoph Rochlitz, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 30, 2016
Burden of symptoms associated with development of metastatic bone disease in patients with breast cancerCharles Cleeland, Roger von Moos, Mark S Walker, et al.
Clinical Genitourinary Cancer|January 29, 2019
Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot StudyMichael Mark, Dirk Klingbiel, Ulrich Mey, et al.
Pageof 13